IFF Specialty Chemicals · Ingredients · Turnaround · Portfolio reset · Thesis updated June 13, 2026

IFF is shrinking toward a cleaner company

Q1 2026 was stronger than expected, with $2.74 billion of net sales and volume growth across all four segments.
Free cash flow improved by $144 million year over year, a key sign that the turnaround is not only an earnings story.
The agreed sale of Food Ingredients to CVC is the main proof point for the portfolio reset.
Management still expects full-year 2026 sales of $10.5 billion to $10.8 billion and EBITDA of $2.05 billion to $2.15 billion.
The near-term test is whether Middle East disruption and higher energy and logistics costs dent Q2 and Q3 margins.

01 Running thesis

A cleaner IFF is taking shape

IFF is in the middle of a self-help story. Management wants a smaller company that is more focused on Taste, Scent, and Health & Biosciences. The agreed sale of Food Ingredients to CVC is the biggest step in that plan.

The latest quarter helped the bull case. Q1 2026 net sales were $2.74 billion, above analyst estimates cited in the transcript, and sales grew 3% on a currency-neutral basis. Adjusted EPS was $1.25, and free cash flow improved by $144 million year over year.

The company also kept its full-year 2026 guide for $10.5 billion to $10.8 billion of sales and $2.05 billion to $2.15 billion of EBITDA. That matters because the company also warned about Q2 pressure from Middle East disruption, higher logistics costs, and higher energy costs.

This is not a clean victory yet. Scent sales grew 1% in Q1, but EBITDA fell 2% because the commodity Fragrance Ingredients business hurt margins. The stock story now depends on closing the Food Ingredients sale, using the cash well, and proving that Q2 cost pressure does not derail the year.

May 2026▲Q1 2026 beat expectations, with $2.74 billion of net sales, adjusted EPS of $1.25, and free cash flow up $144 million year over year. The Food Ingredients sale to CVC moved the portfolio reset from plan to execution.

Feb 2026▲IFF launched a formal sale process for Food Ingredients and ended 2025 with net leverage at 2.6 times, down from 3.8 times a year earlier. Management guided to 1% to 4% currency-neutral sales growth and 3% to 8% EBITDA growth for 2026.

Nov 2025→Q3 2025 showed flat sales but 7% adjusted EBITDA growth and margin expansion. Food Ingredients kept improving, while softness in Health & Biosciences became a watch item.

May 2025▲IFF completed the Pharma Solutions divestiture two months early and reached its below 3 times leverage target. The Food Ingredients margin recovery continued, but management sounded more cautious on consumer demand.

Feb 2025▲Full-year 2024 results showed 6% comparable sales growth and 16% comparable EBITDA growth. Guidance for 2025 pointed to slower growth as the company lapped a stronger year and reinvested.

Nov 2024▲Strong Q3 2024 results led management to raise full-year sales and volume guidance. The planned split of Nourish into Taste and Food Ingredients made the portfolio story easier to track.

Aug 2024▲The turnaround thesis began with a new strategy built around people, customer focus, innovation, and operational excellence. Strong Q2 results supported the plan, but weak consumer demand stayed a key risk.

02 Business model

Paid to solve taste and scent problems

IFF sells ingredients and formulas to makers of food, drinks, perfumes, home care, health products, and industrial products. A customer may ask for a drink to taste sweeter with less sugar, a detergent to smell a certain way, or an enzyme that helps make lactose-free milk.

The company makes money through a mix of science, customer ties, and manufacturing scale. Its better businesses depend on innovation, not only cheap production. That is why management wants more focus on Taste, Scent, and Health & Biosciences.

The weak spot is that some parts of IFF are closer to commodity chemicals. When input, energy, or shipping costs rise faster than prices, margins can fall. That was visible in Scent during Q1 2026.

The balance sheet is part of the model now. Net debt to credit adjusted EBITDA improved to 2.6 times at the end of 2025 from 3.8 times at the end of 2024. The Food Ingredients sale could help that further, depending on how much cash IFF keeps after closing costs and taxes.

03 Product portfolio

What IFF sells

Growth engine

Taste

Taste includes flavors and related food and drink work. In Q1 2026, sales grew 2% to $656 million and EBITDA rose 18% to $153 million.

Cash cow

Food Ingredients

Food Ingredients includes functional ingredients used in food products. Q1 2026 sales grew 3% to $839 million, and IFF has agreed to sell the business to CVC.

Growth engine

Health & Biosciences

This segment includes probiotics, enzymes, Animal Nutrition, and Food Biosciences. Q1 2026 sales rose 5% to $595 million, with EBITDA up 7% to $153 million.

Steady

Scent

Scent includes consumer fragrances, fine fragrances, and fragrance ingredients. Q1 2026 sales grew 1% to $651 million, but EBITDA declined 2% because of commodity ingredient pressure.

Option

Sugar and salt modulation

IFF helps customers make products taste sweeter or saltier with less sugar or salt. This can matter when food companies face health rules or changing consumer tastes.

Option

AI-aided fragrance design

IFF uses tools that help design scents tied to specific emotions. This supports premium fragrance work, where the company can compete on creativity rather than price alone.

04 Business segments

Q1 sales mix

Taste24%modest

Food Ingredients31%modest

Health & Biosciences22%growing fast

Scent24%flat

The segment mix uses Q1 2026 sales from the company transcript: Taste $656 million, Food Ingredients $839 million, Health & Biosciences $595 million, and Scent $651 million. Food Ingredients is still in the mix until the CVC sale closes.

05 Risk factors

What could go wrong

Food Ingredients sale slips or disappoints

High impact · Medium odds

The sale to CVC is the clearest catalyst in the story. If closing takes longer than expected, or if net proceeds are lower than investors hoped, the balance sheet repair story weakens.

We watchClosing timing, final net proceeds, and management comments on debt reduction versus buybacks.

Scent margins stay weak

Medium impact · Medium odds

Scent grew sales in Q1 2026, but EBITDA fell 2%. The issue was the commodity Fragrance Ingredients business and poor price-to-input cost timing. If mix does not move toward specialty products, the segment may keep dragging on results.

We watchScent EBITDA growth, Scent margin, and comments on the Fragrance Ingredients mix.

Middle East disruption hits fine fragrance

Medium impact · Medium odds

Management called out Middle East disruption as a Q2 headwind, especially for Fine Fragrance. This is a near-term risk to sales timing and sentiment.

We watchQ2 and Q3 Fine Fragrance demand, order delays, and regional commentary from management.

Energy and logistics costs outrun pricing

Medium impact · High odds

Higher shipping and energy costs can pressure margins before price surcharges catch up. Management expects some mitigation, but the timing may not fully help until the second half of 2026.

We watchGross margin, EBITDA margin, and whether surcharges are effective in H2 2026.

Consumer demand slows again

High impact · Medium odds

IFF sells into food, beverage, home, personal care, and fragrance markets. If shoppers pull back, customers may delay launches or reduce orders. That would make full-year guidance harder to reach.

We watchVolume growth by segment and management comments on customer order patterns.

06 Quick answers

In one breath

What does International Flavors & Fragrances do?

IFF makes ingredients used in food, drinks, scents, health products, and industrial products. Its products include flavors, fragrances, enzymes, probiotics, and food ingredients.

Why is IFF selling Food Ingredients?

Management wants a simpler company focused on higher-value Taste, Scent, and Health & Biosciences. The sale to CVC should also help repair the balance sheet if proceeds are used well.

What is the main bull case for IFF stock?

The bull case is that IFF is shrinking into a better business. Q1 2026 showed volume growth across all segments, better free cash flow, and progress on the Food Ingredients sale.

What is the main risk for IFF?

The main risk is that near-term cost and demand pressure offsets the turnaround. Investors should watch Scent margins, Q2 and Q3 cost pressure, and the closing of the Food Ingredients sale.